Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × TH 302 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 7 Sarcoma 4 Hypoxia 4 Prostatic Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumors 2 Neuroectodermal Tumors, Primitive 2 Neoplasm Metastasis 2 Melanoma 2 Solid Tumor 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroendocrine Tumors 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Multiple Myeloma 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Castration Resistant Prostate Cancer 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 9 Bevacizumab 8 toripalimab 7 senaparib 7 Fluorodeoxyglucose F18 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Gemcitabine 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02076230 2016-06-10

A Phase 1 TH-302 Mass Balance Trial

Merck KGaA, Darmstadt, Germany

Phase 1 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡